Skip to content

Bextra and Celebrex Securities Fraud

Investors alleged that drugmaker Pfizer violated federal securities laws by making false, misleading or incomplete statements regarding the cardiovascular risks of Celebrex and Bextra. Seeger Weiss helped secure a $486 million settlement on behalf of the investors.


Prior results do not guarantee or predict a similar outcome in any future matter.